Researcher

Yuan Sheng Yang received his doctorate degree from the Department of Chemical Engineering at Vanderbilt University in 2005. Upon graduation, he joined A*STAR’s Bioprocessing Technology Institute (BTI), where he currently heads the Cell Line Development group that develops platform technologies for accelerating cell-line and antibody development. He has published 64 peer reviewed papers, has filed nine patents, and his cell-line and antibody development platform technologies have been licensed to dozens of companies. The CHO cell line platform Yang helped developed in collaboration with industry partners features unrivalled productivity and speed, enabling the development of five antibody drugs into clinical trials.